Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0O9VW
|
||||
| Former ID |
DIB000581
|
||||
| Drug Name |
Lanperisone
|
||||
| Synonyms |
NK-433
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Nervous and musculoskeletal disorders [ICD10:R25-R29] | Phase 3 | [1] | ||
| Company |
Nippon Kayaku Co Ltd
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C15H18F3NO
|
||||
| Canonical SMILES |
C(c1ccc(C(=O)[C@@H](CN2CCCC2)C)cc1)(F)(F)F
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Sodium channel protein type 4 subunit alpha | Target Info | Modulator | [1] | |
| Reactome | Interaction between L1 and Ankyrins | ||||
| References | |||||
| REF 1 | Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J Pharmacol Exp Ther. 2005 Dec;315(3):1237-46. Epub 2005 Aug 26. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.